Diagnostic Algorithm of Common Mature B-Cell Lymphomas by Immunohistochemistry

Wang, Huan You; Zu, Youli

doi:10.5858/arpa.2016-0521-ra

Cited by 25 publications

(18 citation statements)

References 75 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The CD10 positivity noted in some cases (35.3%) reflects that previously described in PBL (42%, 56%, and 67%) . CD10‐positive cases expressed markers of plasma cell differentiation: all cases expressed VS38c and/or MUM1/IRF4, and 50% expressed BLIMP1.…”

Section: Discussionsupporting

confidence: 70%

“…2,20,34 The CD10 positivity noted in some cases (35.3%) reflects that previously described in PBL (42%, 56%, and 67%). 29,35,36 CD10-positive cases expressed markers of plasma cell differentiation: all cases expressed VS38c and/or MUM1/IRF4, and 50% expressed BLIMP1. The occasional CD3 positivity (n = 2), regarded as aberrant, has been rarely described in DLBCL and PBL.…”

Section: Discussionmentioning

confidence: 97%

See 1 more Smart Citation

Extraoral plasmablastic lymphomas in a high human immunodeficiency virus endemic area

et al. 2019

View full text Add to dashboard Cite

Aims Plasmablastic lymphoma (PBL) occurs mainly in immunocompromised individuals, usually secondary to human immunodeficiency virus (HIV) infection. It classically occurs intraorally, but has been described in extraoral locations. The aim of this study was to define the immunophenotype and Epstein–Barr virus (EBV) status in a large single‐centre cohort of extraoral PBL (EPBL) in South Africa, a high‐prevalence HIV setting. Methods and results This retrospective study of 45 EPBLs included patients' age, gender, race, HIV status, and site. Cases were reviewed histologically, and classified morphologically as pure plasmablastic or plasmablastic with plasmacytic differentiation, and assessed immunohistochemically with antibodies against CD45, CD20, CD79a, PAX5, CD138, MUM1/IRF4, BLIMP1, VS38c, Ki67, bcl‐6, CD10, cyclin D1, and human herpesvirus‐8, by the use of standard automated procedures. EBV was assessed by the use of chromogenic in‐situ hybridisation. Tumours were assessed with a fluorescence in‐situ hybridisation (FISH) MYC break‐apart probe. Twenty‐seven PBLs showed pure plasmablastic morphology, and 18 showed plasmacytic differentiation. The male/female ratio was 1.5:1. The anus was the favoured extraoral site (31.1%), followed by lymph nodes (15.6%). All 29 patients with known HIV status were HIV‐positive. The immunohistochemical profile recapitulated that reported for oral PBLs and EPBLs in HIV‐positive and HIV‐negative patients. EBV was positive in 92.5% of PBLs. FISH analysis showed MYC rearrangement in 48% of cases. Conclusion This study showed a strong association of EPBLs with HIV and EBV infection, similarly to the previously described oral PBL. The strong EBV association together with other clinicopathological parameters and an immunohistochemical profile that includes CD45, CD20, MUM1/IRF4, CD138 and Ki67 may be used in distinguishing PBL from diffuse large B‐cell lymphoma and plasma cell myeloma.

show abstract

Section: Discussionsupporting

confidence: 70%

Section: Discussionmentioning

confidence: 97%

Extraoral plasmablastic lymphomas in a high human immunodeficiency virus endemic area

et al. 2019

View full text Add to dashboard Cite

show abstract

“…In cases with monocytic differentiation, which may lack MPO, IHC detection of CD14, CD11c, or cytoplasmic lysozyme (muramidase) may be helpful. B‐lineage assignment is based on CD19 expression, which can also be shown by IHC . The markers corroborating B‐cell lineage that can be detected by IHC are CD79a, Pax5 (Fig.…”

Section: Ihc In the Diagnosis Of Mpalmentioning

confidence: 63%

Multiparameter flow cytometry applications in the diagnosis of mixed phenotype acute leukemia

Porwit

Béné²

2019

Cytometry Part B Clinical

View full text Add to dashboard Cite

Mixed phenotype acute leukemias (MPALs) represent a rare subgroup of acute leukemias with a poor prognosis. Proper diagnosis and classification of MPAL is extremely important for patients' outcome. Morphology and flow cytometry recognize two types of MPAL: the “bilineal” MPAL with the coexistence of two blast populations of different lineage and truly “biphenotypic” MPAL coexpressing markers of more than one lineage in a homogenous blast population, respectively. The WHO 2008 classification further delineated three categories: associated with t(9;22)/BCR‐ABL1 fusion gene, associated with KMT2A (mixed lineage leukemia) rearrangements, and nonotherwise specified. These categories remained unchanged in the WHO2016 update. Molecular studies have further underlined the heterogeneity of MPAL. In this review, rules for the correct assignment of acute leukemia to the MPAL category are discussed, including both flow cytometry and immunohistochemistry on bone marrow or other tissues biopsies. Comparison of the immunophenotypic classification proposals is provided outlining the explorations mandatory for definitive diagnosis. An extensive review of published data summarizes the reported cytogenetic and molecular anomalies. New developments in the understanding of the early stages of hematopoiesis provide clues to the possible etiopathology of these diseases. Finally, current treatment recommendations are summarized and referenced for clinical use, pointing out that allogeneic hematopoietic stem cell transplantation at an early stage should be considered (at least in adult patients). © 2019 International Clinical Cytometry Society

show abstract

“…Presence of classical prolymphocytes in our case did not support the diagnosis of marginal zone lymphoma, which usually shows the presence of villous lymphocytes on PB and BM. Negative interphase FISH for t (11,14) (q13; q32) and immunohistochemistry for cyclin D1 on BM biopsy helped exclude mantle cell lymphoma [10]. Our case had a negative expression of surface IgM and dim expression of surface IgD.…”

Section: An Illustrative Case Of B-cell Prolymphocytic Leukemiamentioning

confidence: 67%